


Novel antibody-peptide conjugate for combatting *Neisseria gonorrhoea* resistance

A novel antibody-peptide conjugate comprised of Oct-TriA1 covalently linked to an anti-*N. gonorrhoeae* monoclonal antibody. The linker can only be cleaved by certain species of bacteria, resulting in a highly specific therapeutic.

Applications: Novel antimicrobials



Features	Benefits
Linker that can only be cleaved by a protease secreted by the gonococcus	Specific and selective killing of pathogenic microbes
Oct-TriA1 is a highly efficacious antibacterial agent	Effective killing of <i>N. gonorrhoeae</i>
Therapeutic is only released in the presence of the gonococcal IgA protease	Minimises non-selective host cell cytotoxicity that limits use of antimicrobial peptides
Modular, plug and play system for targeting, release, and killing of bacterial pathogens	Technology can be adapted for other pathogenic bacteria

Features	Benefits
Monoclonal antibody can be functionalised	Activation of immune killing to potentiate the antimicrobial

Available for

- Co-development
- Consulting
- Licensing

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.

The above information is provided 'as is' without conditions or warranties. Oxford University Innovation makes no representation and gives no warranty that it is the owner of the intellectual property rights in the technology described. © Oxford University Innovation Ltd 2026, Buxton Court, 3 West Way, Oxford, OX2 0JB.